LRP4 mutations promote tumor progression and resistance to anti-PD-1 therapy in recurrent hepatocellular carcinoma
Our results identified novel LRP4 mutations important in recurrent HCC. Inactivating LRP4 mutations were associated with resistance to anti-programmed cell death protein-1 therapy and could be useful biomarkers for precision therapy in patients with recurrent HCC.
Authors
- Yuhang Ye
- Shao‐Lai Zhou (ORCID: https://orcid.org/0000-0002-8526-5221)
- Jian Zhou (ORCID: https://orcid.org/0000-0002-8654-6439)
- Shuangyi Chen
- Chu‐Bin Luo
- Rongqi Sun
- Long Chen (ORCID: https://orcid.org/0000-0003-4925-0572)
- Ning Li (ORCID: https://orcid.org/0000-0003-2987-2809)
- Jia Fan
- Yuxi Zhang (ORCID: https://orcid.org/0000-0002-7041-9195)
- Jingyue Pan
- Kaixuan Liu (ORCID: https://orcid.org/0000-0001-7506-4285)
- Zheng‐Jun Zhou (ORCID: https://orcid.org/0000-0003-4875-6838)
- Zhiqiang Hu (ORCID: https://orcid.org/0000-0002-8842-6035)
- Xinyi Cui (ORCID: https://orcid.org/0000-0003-1411-9558)
- Si-Yuan Pan
Institutions
- Sun Yat-sen University (CN)
- Fudan University (CN)
- Zhongshan Hospital (CN)
- The First Affiliated Hospital, Sun Yat-sen University (CN)
- Precision Research (United States) (US)
Publication Details
- Journal
- Hepatology
- Published
- 2024-12-24
- DOI
- https://doi.org/10.1097/hep.0000000000001212
- Citations
- 4
- Primary Topic
- Ubiquitin and proteasome pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.94